PIK3CA and B-cell chronic lymphocytic leukemia: In 2014, the orally available PI3Kδ inhibitor, CAL-101 (idelalisib), became the first PI3K-targeting agent to receive FDA approval for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in combination with the anti-CD20 antibody, rituximab, and as a monotherapy for the treatment of relapsed small lymphocytic lymphoma (SLL) and follicular lymphoma (FL), after at least two lines of prior therapy [81,82].